Results 111 to 120 of about 4,657 (129)

Alzheimer's Disease: From Molecular Pathogenesis to Disease-Modifying Therapies and Clinical Implementation in Aging Populations. [PDF]

Clin Interv Aging
Zrineh A, Akwan R, Darawsheh R, Nasser A, Elsharkawy MM.   +4 more
europepmc   +1 more source

Pre- and Post-synapses Contain Lecanemab-reactive Amyloid-β in Post-mortem Human Alzheimer’s Disease Brain

Holt K, Chang YY, Li M, Albertini G, Smith C, Tulloch J, De Strooper B, Hardingham GE, Spires-Jones TL.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Lecanemab: Appropriate Use Recommendations

journal of prevention of Alzheimer's disease, The, 2023
R C Petersen, A Atri, R C Petersen
exaly  

Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease

Neurotherapeutics, 2023
Lars Lannfelt, Malin Johannesson, Christer Möller   +2 more
exaly  

Lecanemab in Early Alzheimer’s Disease

New England Journal of Medicine, 2023
Michio Kanekiyo, Larisa Reyderman, Chad J Swanson   +2 more
exaly  

Long-Term Health Outcomes of Lecanemab in Patients With Early Alzheimer’s Disease Using Simulation Modeling

Neurology and Therapy, 2022
Ali Tafazzoli, Amir Abbas Tahami Monfared, Quanwu Zhang   +2 more
exaly  

The Affordability of Lecanemab, an Amyloid-Targeting Therapy for Alzheimer's Disease: An EADC-EC Viewpoint

Lancet Regional Health - Europe, The, 2023
Linus Jönsson, Bengt Winblad, Pierre Jean Ousset   +2 more
exaly  

Lecanemab for Early Alzheimer's Disease: Appropriate Use Recommendations From the French Federation of Memory Clinics

journal of prevention of Alzheimer's disease, The
Matthieu Lilamand, Charlotte Cordonnier, Nicolas Villain   +2 more
exaly  

Monoclonal Therapy With Lecanemab in the Treatment of Mild Alzheimer's Disease: A Systematic Review and Meta-Analysis

Ageing Research Reviews
Neyder Contreras
exaly  

Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease

Annals of Pharmacotherapy
Juliane Park
exaly